Table 3 Univariate and multivariate analysis of clinicopathological variables and PFKFB4 associated with overall survival

Age (years)

 ≤ 50

1

–

–

–

 > 50

1.72 (0.66–4.46)

0.266

–

–

Menopausal status

 Premenopausal

1

–

–

–

 Postmenopausal

1.49 (0.58–3.87)

0.411

–

–

Tumor size (cm)

 ≤ 2

1

–

1

–

 > 2, ≤ 5

1.68 (0.60–4.71)

0.327

2.07 (0.69–6.18)

0.193

 > 5

3.22 (0.39–26.8)

0.279

3.43 (0.33–36.0)

0.304

 Cannot be measured

4.21 (0.50–35.1)

0.184

2.67 (0.24–29.7)

0.425

Lymph node status

 Negative

1

–

1

–

 Positive

2.64 (0.93–7.49)

0.069

3.41 (1.08–10.8)

0.037

Grade

 Grade 1–2

1

–

1

–

 Grade 3

2.36 (0.75–7.45)

0.142

2.01 (0.59–6.85)

0.264

 Unknown

2.22 (0.64–7.65)

0.209

2.56 (0.64–10.2)

0.183

ER status

 Negative

1

–

–

–

 Positive

0.64 (0.24–1.72)

0.371

–

–

PR status

 Negative

1

–

–

–

 Positive

0.70 (0.26–1.89)

0.477

–

–

HER2 status

 Negative

1

–

1

–

 Positive

0.49 (0.17–1.40)

0.184

0.67 (0.14–3.16)

0.617

Subtype^a

 Luminal

1

–

1

–

 HER2-enriched

0.71 (0.15–3.44)

0.675

0.47 (0.068–3.21)

0.439

 Triple-negative

2.10 (0.76–5.79)

0.152

1.13 (0.31–4.17)

0.850

PFKFB4

 Negative

1

–

1

–

 Positive

7.38 (1.69–32.3)

0.008

7.44 (1.67–33.2)

0.009